Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin plazma lipid düzeylerine etkisi

Volume: 13 Number: 3 April 21, 2009
  • Ercan Varol
  • Mehmet Şahin
  • S.murat Aslan
  • Mehmet Özaydın
  • Ahmet Altınbaş
Medical Journal of Süleyman Demirel University Cover
Medical Journal of Süleyman Demirel University
PDF Download

Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin plazma lipid düzeylerine etkisi

Abstract

SüleymanDemirel Üniversitesi TIP FAKÜLTESİ DERGİSİ: 2006 Eylül; 13(3) Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin plazma lipid düzeylerine etkisi Ercan Varol, Mehmet Şahin, S Murat Aslan, Mehmet Özaydın, Ahmet Altınbaş Özet Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin plazma lipid düzeylerine etkisi Kısa dönem, 1 aylık orlistat tedavisinin lipid profili üzerine etkisini araştırmak. Onüç obez hastada düşük kalorili diyete ilave olarak günde 3 kez 120 mg orlistat verildi. Başlangıç ve 1 ay sonraki plazma lipid düzeylerine bakıldı. Trigliserid (TG) seviyesi 169.9 ± 62.7 mg/dl den 156.6 ± 60.4 mg/dl'ye (p<0.05), düşük dansiteli lipoprotein kolesterol (LDL-K) seviyesi 137.7 ± 17.5 mg/dl den 136.1 ± 17.2 mg/dl'ye (p<0.05) ve total kolesterol (TK) seviyesi 222.1 ± 47.3 mg/dl den 220.8 ± 47.6 mg/dl seviyesine düştü (p<0.05). Azalmalar istatistiksel açıdan anlamlı idi. Yüksek dansiteli lipoprotein kolesterol (HDL-K) seviyesindeki artış anlamlı değildi (36.5 ± 2.7 mg/dl den 36.9 ± 2.4 mg/dl' ye; p=0.09). Orlistat kilo verdirici etkisinden bağımsız olarak 1 aylık kısa dönemde lipid profili üzerine olumlu etkiye sahiptir. Anahtar kelımeler: Obezite, Orlistat, Kolesterol, Trigliserid Abstract Effect of short term (1 month) orlistat treatment on plasma lipid levels ın obese patients The aim of the study is to investigate the effect of a short term 1–month orlistat treatment on lipid profile in obese patients. Orlistat was administered three times 120 mg in a day in conjunction with a reduced calorie diet in 13 obese patients. Plasma lipid levels were determined at beginning and 1 month later. The triglyceride level decreased from 169.9 ± 62.7 mg/dl to 156.6 ± 60.4 mg/dl (p<0.05), low density lipoprotein cholesterol level decreased from 137.7 ± 17.5 mg/dl to 136.1 ± 17.2 mg/dl (p<0.05) and total cholesterol level decreased from 222.1 ± 47.3 mg/dl to 220.8 ± 47.6 mg/dl (p<0.05). The changes were statistically significant. The increase in high density lipoprotein cholesterol levels was not statistically significant (36.5 ± 2.7 mg/dl to 36.9 ± 2.4 mg/dl; p=0.09). Orlistat has a beneficial effect on lipid profiles in 1 month short term period in obese patients regardless of weight loss. Key words: Obesity, Orlistat, Cholesterol, Triglyceride

Keywords

References

  1. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB & Patel IH Retrospective population- based analysis of the dose response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56: 82–85.
  2. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disorder 1997; 21 (suppl.3): S12–S23
  3. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP et al. Randomized placebo – controlled trial of orlistat of weight loss and prevention of weight regain in obese patiants. Lancet 1998; 352; 167 – 172
  4. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999; 281: 235–242.
  5. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance and impaired cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000; 8: 49–61.
  6. Kelley DE, Bray GA, Pi-Sunyer. Clinical efficacy of orlistat therapy in owerweight and obese patients with insulin treated-type 2 diabetes: a 1-year randomized controlled trial . Diabetes Care 2002; 25: 1033-41.
  7. Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profili, in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Therapeutics 2003; 25: 1107-22.
  8. Muls E, Kolanowski J, Scheen E, Van Gaal L. The effects of orlistat on weight and serum lipids in obese patients with hypercholestrolemia: a randomized, double blind, placebo controlled, multicentre study. Int J Obes Relat Metab Disord 2001; 25: 1713-21

Details

Primary Language

English

Subjects

-

Journal Section

-

Authors

Mehmet Şahin This is me

S.murat Aslan This is me

Mehmet Özaydın This is me

Ahmet Altınbaş This is me

Publication Date

April 21, 2009

Submission Date

April 20, 2009

Acceptance Date

-

Published in Issue

Year 2006 Volume: 13 Number: 3

DOI

https://doi.org/10.17343/sdutfd.57521

IZ

https://izlik.org/JA63KG97ZZ

Cite

RIS / Bibtex
APA
Varol, E., Şahin, M., Aslan, S., Özaydın, M., & Altınbaş, A. (2009). Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin plazma lipid düzeylerine etkisi. Medical Journal of Süleyman Demirel University, 13(3), 1-3. https://doi.org/10.17343/sdutfd.57521
AMA
1.Varol E, Şahin M, Aslan S, Özaydın M, Altınbaş A. Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin plazma lipid düzeylerine etkisi. Med J SDU. 2009;13(3):1-3. doi:10.17343/sdutfd.57521
Chicago
Varol, Ercan, Mehmet Şahin, S.murat Aslan, Mehmet Özaydın, and Ahmet Altınbaş. 2009. “Obez Hastalarda Kısa Dönem (1 Aylık) Orlistat Tedavisinin Plazma Lipid Düzeylerine Etkisi”. Medical Journal of Süleyman Demirel University 13 (3): 1-3. https://doi.org/10.17343/sdutfd.57521.
EndNote
Varol E, Şahin M, Aslan S, Özaydın M, Altınbaş A (April 1, 2009) Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin plazma lipid düzeylerine etkisi. Medical Journal of Süleyman Demirel University 13 3 1–3.
IEEE
[1]E. Varol, M. Şahin, S. Aslan, M. Özaydın, and A. Altınbaş, “Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin plazma lipid düzeylerine etkisi”, Med J SDU, vol. 13, no. 3, pp. 1–3, Apr. 2009, doi: 10.17343/sdutfd.57521.
ISNAD
Varol, Ercan - Şahin, Mehmet - Aslan, S.murat - Özaydın, Mehmet - Altınbaş, Ahmet. “Obez Hastalarda Kısa Dönem (1 Aylık) Orlistat Tedavisinin Plazma Lipid Düzeylerine Etkisi”. Medical Journal of Süleyman Demirel University 13/3 (April 1, 2009): 1-3. https://doi.org/10.17343/sdutfd.57521.
JAMA
1.Varol E, Şahin M, Aslan S, Özaydın M, Altınbaş A. Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin plazma lipid düzeylerine etkisi. Med J SDU. 2009;13:1–3.
MLA
Varol, Ercan, et al. “Obez Hastalarda Kısa Dönem (1 Aylık) Orlistat Tedavisinin Plazma Lipid Düzeylerine Etkisi”. Medical Journal of Süleyman Demirel University, vol. 13, no. 3, Apr. 2009, pp. 1-3, doi:10.17343/sdutfd.57521.
Vancouver
1.Ercan Varol, Mehmet Şahin, S.murat Aslan, Mehmet Özaydın, Ahmet Altınbaş. Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin plazma lipid düzeylerine etkisi. Med J SDU. 2009 Apr. 1;13(3):1-3. doi:10.17343/sdutfd.57521

                                                                                                                 14791 


Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi/Medical Journal of Süleyman Demirel University is licensed under Creative Commons Attribution-NonCommercial 4.0 International.